By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Cellectis Bioresearch today announced a non-exclusive agreement giving it access to Evrogen's fluorescent proteins.

The deal allows Paris-based Cellectis to incorporate the proteins into its own products, expanding its portfolio of genome engineering tools.

Financial and other terms were not disclosed.

Based in Moscow, Evrogen develops technologies for molecular and cell biology.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Kansas City Star examines issues surrounding newborn genome sequencing.

Researchers say their Research Resource Identifier citation format is catching on, Nature News reports.

In Science this week: the Human Silencing Hub protein complex, and more.

Heads of various research funding agencies discuss how to encourage scientific breakthroughs, ScienceInsider reports.